226 related articles for article (PubMed ID: 29100606)
1. BH3-only protein BIM: An emerging target in chemotherapy.
Shukla S; Saxena S; Singh BK; Kakkar P
Eur J Cell Biol; 2017 Dec; 96(8):728-738. PubMed ID: 29100606
[TBL] [Abstract][Full Text] [Related]
2. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
3. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
4. Anti-apoptotic Bcl-XL protein in complex with BH3 peptides of pro-apoptotic Bak, Bad, and Bim proteins: comparative molecular dynamics simulations.
Lama D; Sankararamakrishnan R
Proteins; 2008 Nov; 73(2):492-514. PubMed ID: 18452209
[TBL] [Abstract][Full Text] [Related]
5. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
[TBL] [Abstract][Full Text] [Related]
6. Targeting the regulatory machinery of BIM for cancer therapy.
Harada H; Grant S
Crit Rev Eukaryot Gene Expr; 2012; 22(2):117-29. PubMed ID: 22856430
[TBL] [Abstract][Full Text] [Related]
7. Loss of BIM in T cells results in BCL-2 family BH3-member compensation but incomplete cell death sensitivity normalization.
Ludwig LM; Roach LE; Katz SG; LaBelle JL
Apoptosis; 2020 Apr; 25(3-4):247-260. PubMed ID: 31993851
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
[TBL] [Abstract][Full Text] [Related]
9. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia.
Zhang LN; Li JY; Xu W
Cancer Gene Ther; 2013 Jan; 20(1):1-7. PubMed ID: 23175245
[TBL] [Abstract][Full Text] [Related]
10. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma.
Mukherjee N; Strosnider A; Vagher B; Lambert KA; Slaven S; Robinson WA; Amato CM; Couts KL; Bemis JGT; Turner JA; Norris DA; Shellman YG
Cell Death Dis; 2018 Sep; 9(9):907. PubMed ID: 30185782
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics.
Gillings AS; Balmanno K; Wiggins CM; Johnson M; Cook SJ
FEBS J; 2009 Nov; 276(21):6050-62. PubMed ID: 19788418
[TBL] [Abstract][Full Text] [Related]
12. Activation of multidomain and BH3-only pro-apoptotic Bcl-2 family members in p53-defective cells.
Paquet C; Schmitt E; Beauchemin M; Bertrand R
Apoptosis; 2004 Nov; 9(6):815-31. PubMed ID: 15505424
[TBL] [Abstract][Full Text] [Related]
13. Endogenous association of Bim BH3-only protein with Mcl-1, Bcl-xL and Bcl-2 on mitochondria in human B cells.
Gomez-Bougie P; Bataille R; Amiot M
Eur J Immunol; 2005 Mar; 35(3):971-6. PubMed ID: 15724238
[TBL] [Abstract][Full Text] [Related]
14. Molecular determinants of Bim(BH3) peptide binding to pro-survival proteins.
Delgado-Soler L; Pinto M; Tanaka-Gil K; Rubio-Martinez J
J Chem Inf Model; 2012 Aug; 52(8):2107-18. PubMed ID: 22794663
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
Turner BC; Eves T; Refaeli Y
DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
[TBL] [Abstract][Full Text] [Related]
16. Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment.
Raghav PK; Verma YK; Gangenahalli GU
Int J Biol Macromol; 2012 Apr; 50(3):796-814. PubMed ID: 22155216
[TBL] [Abstract][Full Text] [Related]
17. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly.
Kuwana T; Bouchier-Hayes L; Chipuk JE; Bonzon C; Sullivan BA; Green DR; Newmeyer DD
Mol Cell; 2005 Feb; 17(4):525-35. PubMed ID: 15721256
[TBL] [Abstract][Full Text] [Related]
18. The chaperone Hsp70 is a BH3 receptor activated by the pro-apoptotic Bim to stabilize anti-apoptotic clients.
Guo Z; Song T; Wang Z; Lin D; Cao K; Liu P; Feng Y; Zhang X; Wang P; Yin F; Dai J; Zhou S; Zhang Z
J Biol Chem; 2020 Sep; 295(37):12900-12909. PubMed ID: 32651234
[TBL] [Abstract][Full Text] [Related]
19. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Deng J; Shimamura T; Perera S; Carlson NE; Cai D; Shapiro GI; Wong KK; Letai A
Cancer Res; 2007 Dec; 67(24):11867-75. PubMed ID: 18089817
[TBL] [Abstract][Full Text] [Related]
20. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL
J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
